GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roivant Sciences Ltd (FRA:87S) » Definitions » Research & Development

Roivant Sciences (FRA:87S) Research & Development : €522.23 Mil (TTM As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Roivant Sciences Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Roivant Sciences's Research & Development for the three months ended in Mar. 2025 was €134.35 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 was €522.23 Mil.

Roivant Sciences Research & Development Historical Data

The historical data trend for Roivant Sciences's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roivant Sciences Research & Development Chart

Roivant Sciences Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Research & Development
198.77 438.60 424.09 404.72 509.13

Roivant Sciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 98.95 123.75 128.91 135.22 134.35

Roivant Sciences Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €522.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roivant Sciences  (FRA:87S) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Roivant Sciences Research & Development Related Terms

Thank you for viewing the detailed overview of Roivant Sciences's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Roivant Sciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roivant Sciences Ltd (FRA:87S) » Definitions » Research & Development
Comparable Companies
RVMD TECH CORT HALO JAZZ BPMC BBIO MDGL ASND TGTX VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
ROIV:USA 87S:Germany
Address
50 Broadway, 7th Floor, London, GBR, SW1H 0BD
Website
https://www.roivant.com
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Roivant Sciences Headlines

No Headlines